Michael Shen
News
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.
A study, led by Professor Michael Shen, published in Cell, details the development of patient-specific bladder cancer organioids that mimic many of the characteristics of actual tumors. The use of organoids may be useful in the future to guide treatment of patients.
The Center for Topology of Cancer Evolution and Heterogeneity will combine new mathematical approaches and single-cell experimental technologies to study cellular diversity in solid tumors.
Biomarker Identified for Predicting Prostate Cancer Aggressiveness
Measurements of the expression levels of three genes associated with aging can be used to better assess which patients with indolent prostate cancer require treatment.
Study Supports Cell-of-Origin Model of Prostate Cancer Heterogeneity
The cell-of-origin model suggests that the aggressiveness of a tumor may result from the type of cell from which it arises. A new study has identified molecular signatures that hold potential as biomarkers of specific prostate cancer subtypes.